Over the past few years
To improve our profile in the investment community and place us on a stronger financial foundation, we have completed a capital restructure and successfully converted approximately
In 2013, our HER2/neu clinical program continued with full recruitment of breast cancer patients, progression through initial safety checkpoint and demonstration of immune responses with interim data expected to be released in the near future. We also saw a major advancement in technology development in our own laboratories with “proof of concept” that our new and novel expression vector technology (PolyStart™) could provide a much greater signal for T-cells to kill abnormal cells and become a platform technology from which we can build out multiple applications and revenue streams. Additional data and information will be forthcoming as we attempt to further secure the intellectual property around this exciting technology advancement.
During 2013, results from our infectious disease program have opened several business development opportunities we expect to solidify by the end of 2014.
Consistent with our new financial structure, we plan to raise sufficient capital to progress our current clinical trials, license-in new clinical programs and expand our technology platforms well into 2015. We intend to also expand our patent portfolio and continue building a top-tier management team. As previously mentioned, the majority of our Company's prior debt has also been retired, further strengthening our overall financial position.
Over the next 12 months, we intend to advance and report on various clinical trials and R&D programs, thereby further strengthening the commercial potential of our comprehensive approach to immunotherapy that is designed to stimulate Helper T-cells and Killer T-cells and to enhance antigen presentation. All of the above considered, we believe makes
HER2/neu Breast Cancer Phase I/II clinical trials – Interim data analysis from our current Phase I trial has demonstrated safety. In addition, we plan to provide an interim analysis of specific T-cell immune responses associated with the first set of patients treated with 4 Class II antigens in the first quarter of 2014. We expect that this Phase I study will be formally completed this year. We plan to have discussions with the
Deeper Pipeline – We have identified additional clinical assets that could enhance and deepen our clinical pipeline. We will provide more information on these opportunities as they develop.
PolyStart™ Technology – We will continue to secure the intellectual property portfolio surrounding our novel expression vector technology in the first quarter and expect to complete the preclinical testing in 2014 for subsequent incorporation into our HER2/neu clinical strategy and other pipeline developments.
Viral Disease Program – We will be reviewing our ongoing collaboration with
Intellectual Property – In addition to licensing new intellectual property surrounding a new clinical program, we intend to file the initial patent for PolyStart™ and continue to develop this technology to solidify and enhance the patent position for a variety of cancers and viral diseases. We plan to be active in acquiring additional immunotherapy technologies that are synergistic with our current approach.
Strategic Collaborations –
We plan to strengthen our relationship with
Co-Development/Out-Licensing – We plan to seek a development partner for commercialization of our smallpox vaccine and viral disease program. While
Development Partnerships -- As we enter Phase II clinical trials and data are generated and published, we believe there will be significant interest from pharmaceutical companies. Because
Stock Market Uplisting – It is the strategic aim of
While we are currently focused on HER2/neu breast and ovarian cancer, our approaches can be explored for use with other cancers including colorectal and metastatic melanoma. Our focus on enhancing antigen presentation, in a prime and boost strategy, gives us the opportunity to make other approaches that are in development or already commercialized for cancer treatment, more effective and to establish
In closing, I thank you, our shareholders and investors, for helping to position
Chairman and Chief Executive Officer
For more information, please visit http://www.tapimmune.com.
Forward-Looking Statement Disclaimer: This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements”. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company’s most recent Form 10-K and other
Chairman and Chief Executive Officer
Most Popular Stories
- India Recognizes Transgender People as 'Third Gender'
- Grand Jury Seated in Rick Perry Ethics Case
- U.S. Homebuilder Confidence Edged Up in April
- Alfonso Wins Executive of the Year Award
- The 420 on the Hemp Products Giveaway
- German Firm Starts Gas Deliveries to Ukraine
- Five Secrets for Keeping a Job
- Study: Casual Marijuana Use May Cause Brain Changes
- Coca-Cola Soda Sales Lose Pop
- Miami Attorney Being Honored for Charity Work